Next Issue
Volume 27, 03
Previous Issue
Volume 26, 11
 
 
cardiovascmed-logo

Journal Browser

Journal Browser
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).

Cardiovasc. Med., Volume 27, Issue 1 (01 2024) – 7 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
9 pages, 527 KB  
Review
A New Therapeutic Principle in Anticoagulation
by Pratintip Lee and Hans-Jürg Beer
Cardiovasc. Med. 2024, 27(1), 8; https://doi.org/10.4414/cvm.2024.1270682599 - 24 Jan 2024
Viewed by 326
Abstract
Thrombosis remains a significant clinical challenge with potential life-threatening consequences. Despite advancements in anticoagulants, concerns about bleeding and the delicate balance of thrombotic risks persist, especially in patients with specific comorbidities such as renal insufficiency, cirrhosis, and those with medical devices. The search [...] Read more.
Thrombosis remains a significant clinical challenge with potential life-threatening consequences. Despite advancements in anticoagulants, concerns about bleeding and the delicate balance of thrombotic risks persist, especially in patients with specific comorbidities such as renal insufficiency, cirrhosis, and those with medical devices. The search for effective anticoagulant therapies that can prevent thrombotic events while minimizing bleeding risks, has led to the emergence of factor XI (FXI) inhibition as a promising approach. These inhibitors target FXI using different mechanisms of action, routes of administration and durations, offering flexibility for various clinical conditions. Early findings from phase II trials have shown a promising trend of reduced bleeding risks in both venous thrombosis and arterial thromboembolism. The results from these trials, particularly the ongoing phase III trials, will yield valuable insights into the efficacy of FXI inhibitors in preventing thrombosis. Specific patient populations, including individuals with end-stage renal disease and those with mechanical devices or blood exposed to artificial surfaces (commonly referred to as artificial contact surfaces associated thrombosis), alongside patients with conditions like thrombotic antiphospholipid syndrome or sickle cell disease, might experience distinct advantages from the application of FXI inhibitors. Dedicated clinical studies focusing on these patient groups are crucial to establish the effectiveness and safety of FXI inhibitors in their management. Moreover, it is imperative to address the development of effective strategies to reverse the anticoagulant effects of FXI inhibitors, ensuring comprehensive patient management, especially for agents with long half-lives. This review article provides a comprehensive overview of the current understanding and research progress in FXI inhibition for thrombosis prevention. Full article
Show Figures

Figure 1

1 pages, 119 KB  
Editorial
A Tribute to Istvan Babotai, PhD
by Etienne Delacrétaz and Christian Sticherling
Cardiovasc. Med. 2024, 27(1), 6; https://doi.org/10.4414/cvm.2024.1282909062 - 24 Jan 2024
Viewed by 92
Abstract
In 1956, at the age of 17, Istvan Babotai fled Hungary, became an electrical engineer and ultimately a pioneering figure of cardi ac pacing in Switzerland [...] Full article
2 pages, 132 KB  
Commentary
Of Nutty Professors and Pristine Coronary Arteries
by Franz H. Messerli, Manuel R. Blum and Bernhard Meier
Cardiovasc. Med. 2024, 27(1), 31; https://doi.org/10.4414/cvm.2024.1262905452 - 24 Jan 2024
Viewed by 100
Abstract
“Professor Meier is nuts!” [...] Full article
Show Figures

Figure 1

3 pages, 297 KB  
Case Report
Personalized Management of Coronary Atherosclerosis
by Apostolos Tsinaridis, Marko Gajic, Alessandro Candreva, Philipp A. Kaufmann, Ronny R. Buechel, Barbara E. Stähli and Andreas A. Giannopoulos
Cardiovasc. Med. 2024, 27(1), 28; https://doi.org/10.4414/cvm.2024.1246902814 (registering DOI) - 24 Jan 2024
Viewed by 80
Abstract
We present the diagnostic pathway and management of an asymptomatic patient with a solitary, potentially high-risk coronary plaque, utilizing modern and advanced non-invasive and invasive pathophysiological, morphological, and functional assessment. By using coronary computed to mography angiography, computer-based solutions were employed enabling non-invasive [...] Read more.
We present the diagnostic pathway and management of an asymptomatic patient with a solitary, potentially high-risk coronary plaque, utilizing modern and advanced non-invasive and invasive pathophysiological, morphological, and functional assessment. By using coronary computed to mography angiography, computer-based solutions were employed enabling non-invasive under standing of the plaque characteristics and the local and global functional micro-environment. Invasive coronary angiography-based, computational, and wire-free hemodynamic lesion assess ment as well as intracoronary imaging with optical coherence tomography were further utilized, allowing for personalized management and guiding coronary revascularization. Full article
3 pages, 400 KB  
Case Report
Conservative Treatment of Permanent Junctional Reciprocating Tachycardia
by Tatiana Peer and Andreas Müller-Burri
Cardiovasc. Med. 2024, 27(1), 25; https://doi.org/10.4414/cvm.2024.1243919841 (registering DOI) - 24 Jan 2024
Viewed by 95
Abstract
Permanent junctional reciprocating tachycardia (PJRT) is a rare form of atrioventricular reentrant tachycardia due to an accessory pathway characterized by slow and decremental retrograde con duction. The arrhythmia typically presents before adulthood with incessant tachycardia leading to cardiomyopathy and heart failure. We report [...] Read more.
Permanent junctional reciprocating tachycardia (PJRT) is a rare form of atrioventricular reentrant tachycardia due to an accessory pathway characterized by slow and decremental retrograde con duction. The arrhythmia typically presents before adulthood with incessant tachycardia leading to cardiomyopathy and heart failure. We report the case of a woman with tachycardia induced cardiomyopathy due to PJRT detected at the age of 54 years. The patient refused to undergo catheter ablation and was successfully treated with a beta blocker. Full article
5 pages, 237 KB  
Article
Specialized Clinical Care Pathway for Non-ST-Elevation Myocardial Infarction
by Jérôme Dällenbach, Grégoire Girod, Pierre Monney, Wongsakorn Luangphiphat and Eric Eeckhout
Cardiovasc. Med. 2024, 27(1), 18; https://doi.org/10.4414/cvm.2024.1220454347 - 24 Jan 2024
Viewed by 220
Abstract
Background: The mortality reduction associated with immediate coronary reperfusion in patients with ST-elevation myocardial infarction is extensively documented. The gap between available knowledge and care delivery is primarily due to lacking coordination between the patient contact points. We postulate that the same applies [...] Read more.
Background: The mortality reduction associated with immediate coronary reperfusion in patients with ST-elevation myocardial infarction is extensively documented. The gap between available knowledge and care delivery is primarily due to lacking coordination between the patient contact points. We postulate that the same applies to non-ST-elevation myocardial infarction (NSTEMI) and that a more consistent care delivery could improve outcomes. Methods: We conducted a single-center retrospective observational study in NSTEMI patients who presented to the emergency department (ED) at our institution between October 2017 and September 2019, covering the last twelve months before implementing our new NSTEMI care pathway (pre-intervention) and the first twelve months thereafter (post-intervention). Primary endpoint was the door-to-cardiology time, i.e., time between ED admission and admission to the cardiology department. Co-primary endpoint was the door-to-needle time, i.e., time between ED admission and initiation of coronary angiography. Secondary endpoints included total hospital stay (time between ED admission and discharge), in-hospital mortality (%), and retrospective misdiagnoses with the coronary angiography showing no or non-relevant coronary lesions (%). Results: 271 consecutive NSTEMI patients were treated during the study period. 112 (41.3%) in the year before and 159 (58.7%) in the year after the NSTEMI care pathway implementation. NSTEMI care pathway led to a significant reduction in median door-to-cardiology time from twelve hours (interquartile range [IQR] 6–24 h) pre-intervention to six hours (IQR 4–9 h) post-intervention (p < 0.0001); a significant reduction in median length of hospital stay from five days (IQR 3–10 days) pre-intervention to three days (IQR 2–7 days) post-intervention (p <0.0001); and a significant reduction of misdiagnoses from 16.96% pre-intervention to 8.81% post-intervention (p = 0.0341). There was no significant change in median door-to-needle time (28 h pre-intervention to 24 h post-intervention, p = 0.0736) nor in in-hospital mortality (0.89% pre-intervention versus 2.52% post-intervention, p = 0.6519). Conclusions: The NSTEMI care pathway significantly reduced door-to-cardiology time, length of hospital stay and number of misdiagnoses. It proved feasible in routine clinical practice and could be implemented on a larger scale. Full article
Show Figures

Figure 1

3 pages, 223 KB  
Editorial
Cardiac Sarcoidosis—An Underrecognized Myocardial Disease
by Thomas F. Lüscher, Rakesh Sharma, Kshama Wechalekar and Vasileios Kouranos
Cardiovasc. Med. 2024, 27(1), 1; https://doi.org/10.4414/cvm.2024.1324050930 - 24 Jan 2024
Viewed by 168
Abstract
Sarcoidosis is a multisystemic, chronic inflamma tory disorder involving lymph nodes and lungs characterized by a non-caseating [...] Full article
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop